Consensus of the Brazilian Society of Rheumatology for the diagnosis, management and treatment of lupus nephritis;Consenso da Sociedade Brasileira de Reumatologia para o diagnóstico, manejo e tratamento da nefrite lúpica

Revista Brasileira de Reumatologia

Volumn 55, Issue 1, 2015, Pages 1-21

  Klumb, Evandro Mendes ^a   Silva, Clovis Artur Almeida ^b   Lanna, Cristina Costa Duarte ^c   Sato, Emilia Inoue ^d   Borba, Eduardo Ferreira ^b   Brenol, João Carlos Tavares ^e   de Albuquerque, Elisa Martins das Neves ^a   Monticielo, Odirlei Andre ^e   Costallath, Lilian Tereza Lavras ^f   Latorre, Luiz Carlos ^g   Sauma, Maria de Fátima Lobato da Cunha ^h   Bonfá, Eloisa Silva Dutra de Oliveira ^b   Ribeiro, Francinne Machado ^a  

^a UNIVERSIDADE DO ESTADO DO RIO DE JANEIRO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^e FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^f UNIVERSITY OF CAMPINAS   (Brazil)

^g Heliopolis General Hospital   (Brazil)

^h FEDERAL UNIVERSITY OF PARÁ   (Brazil)

Author keywords

Brazil; Consensus; Lupus nephritis; Systemic lupus erythematous; Therapeutics

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CHLOROQUINE; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; BRAZIL; CLINICAL FEATURE; CONSENSUS DEVELOPMENT; DIAGNOSTIC PROCEDURE; DRUG CONTRAINDICATION; DRUG USE; HISTOPATHOLOGY; HUMAN; INFECTION RISK; KIDNEY BIOPSY; LABORATORY TEST; LUPUS ERYTHEMATOSUS NEPHRITIS; MEDICAL DECISION MAKING; MEDICAL SOCIETY; MEMBRANOUS GLOMERULONEPHRITIS; PATIENT CARE; PRACTICE GUIDELINE; PROLIFERATIVE GLOMERULONEPHRITIS; REMISSION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; BIOPSY; DISEASE COURSE; LUPUS NEPHRITIS;

BIOPSY; BRAZIL; DISEASE PROGRESSION; HUMANS; LUPUS NEPHRITIS; REMISSION INDUCTION;

EID: 84928016618     PISSN: 04825004     EISSN: 18094570     Source Type: Journal    
DOI: 10.1016/j.rbr.2014.09.008     Document Type: Article

References (205)

1. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54:2550-7.
2. Souza DC, Santo AH, Sato EI. Mortality profile related to systemic lupus erythematosus: a multiple cause-of-death analysis. Journal of Rheumatology. 2012;39:496-503.
3. Telles RW, Lanna CCD, Souza FL, Rodrigues LA, Reis RCP, Ribeiro AL. Causes and predictors of death in Brazilian lupus patients. Rheumatol Int. 2013;33:467-73.
4. Beck LH Jr, Salant DJ. Treatment of membranous lupus nephritis: where are we now? J A m Soc Nephrol. 2009;20(4):690-1. PMID: 19279123.
5. Kang KY, Kwok SK, Ju JH, Park KS, Cho CS, Kim HY, Park SH. The causes of death in Korean patients with systemic lupus erythematosus over 11 years. Lupus. 2011;20:989-97.
6. Yap DY, Yu X, Chen XM, Lu F, Chen N, Li XW, et al. Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome. Nephrology. 2012;17:352-7.
7. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, De Ramon Garrido E, Danieli MG, et al. Th 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69(1):61-4 PMID: 19155235.
8. Rabbani MA, Habib HB, Islam M, Ahmad B, Majid S, Saeed W, Shah SMA, Ahmad A. Survival analysis and prognostic indicators of systemic lupus erythematosus in Pakistani patients. Lupus. 2009;18:848-55.
9. Ribeiro FM, Fabris CL, Bendet I, Lugon JR. Survival of lupus patients on dialysis: a Brazilian cohort. Rheumatol. 2013;52:494-500.
10. Dooley MA. Clinical and laboratory features of lupus nephritis. In: Wallace DJ, Hahn BH, editors. Duboi's lupus erythematosus. 7 th ed. Philadelphia: Lippincott Williams & Wilkins; 2007.
11. Nived O, Hallengren CS, Alm P, Jonsen A, Sturfelt G, Bengtsson AA. An observational study of outcome in SLE patients with biopsy-verified glomerulonephritis between 1986 and 2004 in a defined area of Southern Sweden: the clinical utility of the ACR renal response criteria and predictors for renal outcome. Scand J Rheumatol. 2013;42(5):383-9.
12. Markowitz GS, D'Agati VD. Classification of lupus nephritis. Curr Opin Nephrol Hypertens. 2009;18(3):220-5. Review. PubMed PMID: 19374008.
13. Bomback AS, Appel GB. Updates on the treatment of lupus nephritis. J Am Soc Nephrol. 2010;21(12):2028-35. PMID: 21051743.
14. Hergessel O, Felten H, Andrassy K, Kuhn K, Ritz E. Safety of ultrasound-guided percutaneous renal biopsy-retrospective analysis of 1090 consecutive cases. Nephrol Dial Transplant. 1998;13:975-7.
15. Zhang X, Nagaraja HN, Nadasdy T, Song H, McKinley A, Prosek J, et al. A composite urine biomarker reflects interstitial inflammation in lupus nephritis kidney biopsies. Kidney Int. 2012;81(4):401-6. PMID: 21993584.
16. Mok CC, Ying KY, Ng WL, Lee KW, To CH, Lau CS, et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med. 2006;119:355, e25-355.e33.
17. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC, for the Toronto Glomerulonephritis Registry Group, 2004. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney International. 2004;66:1199-205.
18. Chen YE, Korbet SM, Katz RS, Schwartz MM, Lewis EJ, for the Collaborative Study Group. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol. 2008;3:46-53.
19. Moore RA, Derry S. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther. 2006;8(6):R182. PubMed PMID: 17163990.
20. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 2012;64(6):797-808.
21. Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (Eular/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771-82.
22. Giannico G, Fogo AB. Lupus nephritis: is the kidney biopsy currently necessary in the management of lupus nephritis? Clin J Am Soc Nephrol. 2013;8(1):138-45.
23. Grande JP, Ballow JE. Renal biopsy in lupus nephritis. Lupus. 1998;7:611-7.
24. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15(2):241-50.
25. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65(2):521-30. PMID: 14717922.
26. Daleboudt G, Bajema I, Goemaere N, Van Laar J, Bruijn J, Berger S. The clinical relevance of a repeat biopsy in lupus nephritis flares. Nephrol Dial Transplant. 2009;24:3712-7.
27. Sidiropoulos P, Kritikos H, Boumpas D. Lupus nephritis flares. Lupus. 2005;14:49-52.
28. Arends S, Grootscholten C, Derksen RH, Berger SP, De Sevaux RG, Voskuyl AE, et al. Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis. Ann Rheum Dis. 2012;71(6):966-73.
29. Mok CC. Understanding lupus nephritis: diagnosis, management, and treatment options. Int J Womens Health. 2012;4:213-22.
30. Saxena R, Mahajan T, Mohan C. Lupus nephritis: current update. Arthritis Res Ther. 2011;13(5):240.
31. Cameron JS. Lupus nephritis. J Am Soc Nephrol. 1999;10:413-24.
32. Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, Rohde RD. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis. 2000;35:904-14.
33. Contreras G, Pardo V, Cely C, Borja E, Hurtado A, De La Cuesta C, et al. Factors associated with poor outcomes in patients with lupus nephritis. Lupus. 2005;14(11):890-5.
34. Tektonidou MG, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum. 2004;50(8):2569-79.
35. Brunner HI, Bennett MR, Mina R, Suzuki M, Petri M, Kiani AN, et al. Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis. Arthritis Rheum. 2012;64(8):2687-97.
36. Do Nascimento AP, Viana S, Testagrossa A, Leon EP, Borba EF, Barros RT, Bonfa E. Antibodies to ribosomal P proteins: a potential serologic marker for lupus membranous glomerulonephritis. Arthritis Rheum. 2006;54(5):1568-72.
37. De Macedo PA, Borba EF, Viana Vdos S, Leon EP, Testagrossa A, Barros RT, et al. Antibodies to ribosomal P proteins in lupus nephritis: a surrogate marker for a better renal survival? Autoimmun Rev. 2011;10(3):126-30.
38. Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology Response Criteria for Proliferative and Membranous Renal Disease in Systemic Lupus Erythematosus Clinical Trials. Arthritis Rheum. 2006;54(2):421-32.
39. Navarra SV, Leynes MS. Infections in systemic lupus erythematosus. Lupus. 2010;19:1419-24.
40. Zandman-Goddard G, Shoenfeld Y. Infections and systemic lupus erythematosus. Autoimmunity. 2005;38:473-85.
41. Ribeiro FM, Szyper-Kravitz M, Klumb EM, Lannes G, Ribeiro FR, Albuquerque EM, Shoenfeld Y. Can lupus flares be associated with tuberculosis infection? Clin Rev Allergy Immunol. 2010;38(2-3):163-8.
42. Sciascia S, Cuadrado MJ, Karim MY. Management of infection in systemic lupus erythematosus. Best Practice&Research Clinical Rheumatology. 2013;27:377-89.
43. Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, Martinez-Berriotxoa A, Egurbide MV, Aguirre C. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther. 2009;11:R109.
44. Van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF Dougados M, et al. EULAR Recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70:414-22.
45. Abu-Shakra M. Safety of vaccination of patients with systemic lupus erythematosus. Lupus. 2009;18:1205-8.
46. Campos LM, Silva CA, Aikawa NE, Jesus AA, Moraes JC, Miraglia J, et al. High disease activity: an independent factor for reduced immunogenicity of the pandemic influenza a vaccine in patients with juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2013;65(7):1121-7.
47. Silva CA, Aikawa NE, Bonfa E. Vaccinations in juvenile chronic inflammatory diseases: an update. Nat Rev Rheumatol. 2013;9(9):532-43.
48. Elkayam O, Paran D, Caspi D, Litinsky I, Yaron M, Charboneau D, et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis and systemic lupus erythematosus. Clinical Infectious Diseases. 2002;34:147-53.
49. Abu-Shakra M, Press J, Varsano N, Levy V, Mendelson E, Sukenik S, et al. Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol. 2002;29:2555-7.
50. Gaitonde S, Pathan E, Sule A, Mittal G, Joshi VR. Efficacy of isoniazid prophylaxis in patients with systemic lupus erythematosus receiving long term steroid treatment. Ann Rheum Dis. 2002;61(3):251-3.
51. Gupta D, Zachariah A, Roppelt H, Patel AM, Gruber BL. Prophylatic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophosphamide: a survey of U.S. rheumatologists and review of literature. J Clin Rheumatol. 2008;14:267-72.
52. Austin III HA, Klippel JH, Balow JE, Le Riche NG, Steinberg AD, Plotz PH, Decker JL. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986;314(10):614-9.
53. Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med. 2001 Aug 21;135(4):248-57.
54. Boumpas DT, Austin III H.A., Vaughan EM, Yarboro CH, Klippel JH, Balow JE. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med. 1993;119:366-9.
55. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20:1103-12.
56. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353:2219-28.
57. Ong LM1, Hooi LS, Lim TO, Goh BL, Ahmad G, Ghazalli R, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton). 2005;10(5):504-10.
58. Mak A, Cheak AA, Tan JY, Su HC, Ho RC, Lau CS. Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. Rheumatology (Oxford). 2009;48(8):944-52.
59. Touma Z, Gladman DD, Urowitz MB, Beyene J, Uleryk EM, Shah PS. Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. J Rheumatol. 2011;38(1):69-78.
60. Liu LL, Jiang Y, Wang LN, Yao L, Li ZL. Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials. Drugs. 2012;72(11):1521-33.
61. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, De Ramon Garrido E, Danieli MG, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term follow-up of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum. 2004;50(12):3934-40.
62. Lee YH, Woo JH, Choi SJ, Ji JD, Song GG. Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis. Lupus. 2010;19(6):703-10.
63. McKinley A, Park E, Spetie D, Hackshaw KV, Nagaraja S, Hebert LA, Rovin BH. Oral cyclophosphamide for lupus glomerulonephritis: an underused therapeutic option. Clin J Am Soc Nephrol. 2009;4(11):1754-60.
64. Mok CC, Ho CT, Siu YP, Chan KW, Kwan TH, Lau CS, Wong RW, Au TC. Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens. Am J Kidney Dis. 2001;38(2):256-64.
65. Yee C, Gordon C, Dostal C, Petera P Dadoniene J, Griffiths B, et al. Eular randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis. 2004;63(5):525-9.
66. Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford). 2010;49:128-40.
67. Walsh M, Solomons N, Lisk L, Jayne DR. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva Lupus Management Study. Am J Kidney Dis. 2013;61(5):710-5.
68. Boumpas DT, Austin III H.A., Vaughan EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992;340:741-5.
69. Grootscholten C, Dieker JWC, McGrath FD, Roos A, Derksen RHWM, van der Vlag J, et al. A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/methylprednisolone. Ann Rheum Dis. 2007;66(5):693-6.
70. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido ER, Daniel MG, et al. Immunosuppressive therapy in lupus nephritis. The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46(8):2121-31.
71. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N England J Med. 2011;365(20):1886-95.
72. Houssiau FA, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the Maintain Nephritis Trial. Ann Rheum Dis. 2010;69:2083-9.
73. Moroni G, Gallelli B, Quaglini S, Banfi G, Rivolta E, Messa P, et al. Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrology Dialysis Transplantation. 2006;21:1541-8.
74. Houssiau FA, Lauwerys BR. Current management of lupus nephritis. Best Pract Res Clin Rheumatol. 2013;27(3):319-28.
75. Boumpas DT, Bertsias GK, Balow JE. A decade of mycophenolate mofetil for lupus nephritis: is the glass half-empty or half-full? Ann Rheum Dis. 2010;69:2059-61.
76. Huong PLD, Papo T, Beaufils H, Wechsler B, Bletry O, Baumelou A, et al. Renal involvement in systemic lupus erythematosus: a study of 180 patients from a single center. Medicine. 1999;78:148-66.
77. Ponticelli C, Moroni G. Renal biopsy in lupus nephritis-what for, when and how often? Nephrol Dial Transplant. 1998;13:2452-4. PMID: 9794536.
78. Zabaleta-Lanz M, Vargas-Arenas RE, Tapanes F, Daboin I, Atahualpa Pinto J, Bianco NE. Silent nephritis in systemic lupus erythematosus. Lupus. 2003;12:26-30.
79. Chan TM, Li FK, Hao WK, Chan KW, Lui SL, Tang S, Lai KN. Treatment of membranous lupus nephritis with nephritic syndrome by sequential immunosuppression. Lupus. 1999;8:545-51.
80. Mok CC. Membranous nephropathy in systemic lupus erythematosus: a therapeutic enigma. Nat Rev Nephrol. 2009;5:212-20.
81. Chen G, Liu H, Liu F. A glimpse of the glomerular milieu: From endothelial cell to thrombotic disease in nephrotic syndrome. Microvasc Res. 2013;89:1-6, dx.doi.org/10.1016/j.mvr.2013.06.011.
82. Austin HA, Illei GG. Membranous lupus nephritis. Lupus. 2005;14:65-71.
83. Mok CC, Ying KY, Lau CS, Yim CW, Ng WL, Wong WS, Au TC. Treatment of pure membranou lupus nephropathy with prednisone and azathioprine: an open-label trial. Am J Kidney Dis. 2004;43:269-76.
84. Hallegua D, Wallace DJ, Metzger AL, Rinaldi RZ, Klinenberg JR. Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature. Lupus. 2000;9(4):241-51.
85. Austin III H.A., Illei GG, Braun MJ, Balow JE. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol. 2009;20:901-11. PMID: 19297556.
86. Radhakrishnan J, Moutzouris DA, Ginzler EM, Solomons N, Siempos II, Appel GB. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int. 2010;77:152-60. PMID: 19890271.
87. Kasitanon N, Fine DM, Haas M, Magder LS, Petri M. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus. 2006;15:366-70. PMID: 16830883.
88. Gourley MF, Austin HA III, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: a randomized, controlled trial. Ann Intern Med. 1996;125:549-57.
89. Erre GL, Bosincu L, Faedda R, Fenu P, Masala A, Sanna M, et al. Antiphospholipid syndrome nephropathy (APSN) in patients with lupus nephritis: a retrospective clinical and renal pathology study. Rheumatol Int. 2014;34(4):535-41.
90. Pons-Estel GJ, Cervera R. Renal involvement in antiphospholipid syndrome. Curr Rheumatol Rep. 2014;16(2):397.
91. Galindo M, Gonzalo E, Martinez-Vidal MP, Montes S, Redondo N, Santiago B, et al. Immunohistochemical detection of intravascular platelet microthrombi in patients with lupus nephritis and anti-phospholipid antibodies. Rheumatology (Oxford). 2009;48(8):1003-7.
92. Shen YM, Lee R, Frenkel E, Sarode R. IgA antiphospholipid antibodies are an independent risk factor for thromboses. Lupus. 2008;17(11):996-1003.
93. Zheng H, Chen Y, Ao W, Shen Y, Chen XW, Dai M, et al. Antiphospholipid antibody profiles in lupus nephritis with glomerular microthrombosis: a prospective study of 124 cases. Arthritis Res Ther. 2009;11(3):R93.
94. Silvarino R, Sant F, Espinosa G, Pons-Estel G, Sole M, Cervera R, et al. Nephropathy associated with antiphospholipid antibodies in patients with systemic lupus erythematosus. Lupus. 2011;20(7):721-9.
95. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306.
96. Cervera R, Tektonidou MG, Espinosa G, Cabral AR, Gonzalez EB, Erkan D, et al. Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions. Lupus. 2011;20(2):165-73.
97. D'Cruz D. Renal manifestations of the antiphospholipid syndrome. Curr Rheumatol Rep. 2009;11(1):52-60.
98. Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, Brey R, Crowther M, Derksen R, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011;20(2):206-18.
99. Danowski A, Rego J, Kakehasi AM, Funke A, Carvalho JF, Lima IV, et al. Guidelines for the treatment of antiphospholipid syndrome. Rev Bras Reumatol. 2013;53(2):184-92.
100. Belmont HM. Treatment of systemic lupus erythematosus - 2013 update. Bull Hosp Jt Dis. 2013;71(3):208-13.
101. Schur PH, Wallace DJ. Overview of the therapy and prognosis of systemic lupus erythematosus in adults. 2014, http://www.uptodate.com/contents. Acessado em 15 de agosto de.
102. Petri M, Bello KJ, Fang H, Magder LS. Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio. Arthritis Rheum. 2013;65(7):1865-71.
103. Ruiz-Irastorza G, Gordo S, Olivares N, Egurbide MV, Aguirre C. Changes in vitamin D levels in patients with systemic lupus erythematosus: Effects on fatigue, disease activity, and damage. Arthritis Care Res (Hoboken). 2010;62(8):1160-5.
104. Praga M. Slowing the progression of renal failure. Kidney Int Suppl. 2002;80:18-22.
105. Mann JFE, Bakris GL. Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults. http://www.uptodate.com/contents/. Accessado em 7 de abril de 2014.
106. Mann JFE. What's new in hypertension 2010? Nephrol Dial Transplant. 2011;26:50-5.
107. Duran-Barragan S, McGwin G Jr, Vila LM, Reveille JD, Alarcon GS. Lumina (LIX) a multiethnic US cohort. Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus-results from Lumina (LIX): a multiethnic US cohort. Rheumatology (Oxford). 2008;47(7):1093-6.
108. Kanda H, Kubo K, Tateishi S, Sato K, Yonezumi A, Yamamoto K, Mimura T. Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy. Lupus. 2005;14(4):288-92.
109. Tse KC, Li FK, Tang S, Tang CS, Lai KN, Chan TM. Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria. Lupus. 2005;14(12):947-52.
110. Susantitaphong P, Sewaralthahab K, Balk EM, Eiam-ong S, Madias NE, Jaber BL. Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis. Am J Hypertens. 2013;26(3):424-41.
111. Fessler BJ, Alarcon GS, McGwin G Jr, Roseman J, Bastian HM, Friedman AW, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 2005;52(5):1473-80.
112. Pons-Estel GJ, Alarcon GS, McGwin G Jr, Danila MI, Zhang J, Bastian HM, et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum. 2009;61(6):830-9.
113. Tsakonas E, Joseph L, Esdaile JM, Choquette D, Senecal JL, Cividino A. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus. 1998;7(2):80-5.
114. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69(1):20-8.
115. MarmorMF, KellnerU, LaiTY, Lyons JS, MielerWF. American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118(2):415-22.
116. Culwell KR, Curtis KM, del Carmen Cravioto M. Safety of contraceptive method use among women with systemic lupus erythematosus a systematic review. Obstet Gynecol. 2009;114 2 Pt 1:341-53.
117. Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005;142:953-62.
118. Petri MA, Kiani AN, Post W, Christopher-Stine L, Magder LS. Lupus Atherosclerosis Prevention Study (Laps). Ann Rheum Dis. 2011;70(5):760-5.
119. Plazak W, Gryga K, Dziedzic H, Tomkiewicz-Pajak L, Konieczynska M, Podolec P Musial J. Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study. Arthritis Res Ther. 2011;13(4): R117.
120. Berden JHM. Lupus nephritis. Kidney Int. 1997;52:538-58.
121. Ginzler EM1, Schorn K. Outcome and prognosis in systemic lupus erythematosus Rheum Dis Clin North Am. 1988;14(1):67-78.
122. Clark WF, Moist LM. Management of chronic renal insufficiency in lupus nephritis: role of proteinuria, hypertension and dyslipidemia in the progression of renal disease. Lupus. 1998;7:649-53.
123. Najafi CC, Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int. 2001;59:2156-63.
124. Hill GS, Delahousse M, Nochy D, Mandet C, Bariety J. Proteinuria and tubulointerstitial lesions in lupus nephritis. Kidney Int. 2001;60:1893-903.
125. Hill GS, Delahousse M, Nochy D, Thervet E, Vrtovsnik F, Remy P, et al. Outcome of relapse in lupus nephritis: roles of reversal of renal fibrosis and response of inflammation to therapy. Kidney Int. 2002;61:2176-86.
126. Daugas E, Nochy D, Huong du LT, Duhaut P, Beaufils H, Caudwell V, Bariety J, Piette JC, Hill G. J Am Soc Nephrol. 2002;13:42-52.
127. Tektonidou MG. Renal involvement in the antiphospholipid syndrome (APS)-APS nephropathy. Clin Rev Allergy Immunol. 2009;36(2-3):131-40.
128. Sciascia S, Cuadrado MJ, Khamashta M, Roccatello D. Renal involvement in antiphospholipid syndrome. Nature Rev Nephrol. 2014;10:279-89.
129. Illei GG, Austin HA III, Crane M, Collins L, Gourley MF, Yarboro CH, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med. 2001;135:248-57.
130. Oliveira-Santos M, Verani JFS, Klumb EM, Albuquerque EMN. Evaluation of adherence to drug treatment in patients with systemic lupus erythematosus in Brazil. Lupus. 2011;20(3):320-9.
131. Pagni F, Galimberti S, Goffredo P, Basciu M, Malachina S, Pilla D, et al. The value of repeat biopsy in the management of lupus nephritis: an international multicentre stud in a large cohort of patients. Nephrol Dial Transplant. 2013;28(12):3014-23.
132. Leandro M, Cambridge G, Edwards J, Ehrenstein M, Isenberg D. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology. 2005;44:1542-5.
133. Lu TY, Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London: the first fifty patients. Arthritis Rheum. 2009;15:482-7.
134. Rovin BA, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis. The lupus nephritis assessment with rituximab study. Arthritis Rheum. 2012;64:1215-26.
135. Zavada J, Pesickova S, Rysava R, Olejarova M, Horak P, Hrnclr Z, et al. Cyclosporine or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. Lupus. 2010;19(11):1281-9.
136. Chen W, Tang X, Liu Q, Chen W, Fu P, Liu F, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. Am J Kidney Dis. 2011;57(2):235-44.
137. Chen W, Liu Q, Chen W, Tang X, Fu P, Liu F, et al. Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicente randomized clinical trial. Lupus. 2012;21(9):944-52.
138. Wang S, Li X, Qu L, Wang R, Chen Y, Li Q, et al. Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study. Lupus. 2012;21(9):1025-35.
139. Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;26(9767):721-31, 377.
140. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918-30.
141. Dooley MA, Houssiau F, Aranow C, D'Cruz DP, Askanase A, Roth DA, Zhong ZJ, et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus. 2013;22(1):63-72.
142. Faco MM, Leone C, Campos LM, Febronio MV, Marques HH, Silva CA. Risk factors associated with the death of patients hospitalized for juvenile systemic lupus erythematosus. Braz J Med Biol Res. 2007;40(7):993-1002.
143. Silva CA, Avcin T, Brunner HI. Taxonomy for systemic lupus erythematosus with onset before adulthood. Arthritis Care Res (Hoboken). 2012;64(12):1787-93.
144. Tucker LB, Menon S, Schaller JG, Isenberg DA. Adult and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome. Br J Rheumatol. 1995;34(9):866-72.
145. Costallat LT, Coimbra AM. Systemic lupus erythematosus: clinical and laboratory aspects related to age at disease onset. Clin Exp Rheumatol. 1994;12(6):603-7.
146. Araujo DB, Borba EF, Silva CA, Campos LM, Pereira RM, Bonfa E, Shinjo SK. Alveolar hemorrhage: distinct features of juvenile and adult onset systemic lupus erythematosus. Lupus. 2012;21(8):872-7.
147. Barsalou J, Levy DM, Silverman ED. An update on childhood-onset systemic lupus erythematosus. Curr Opin Rheumatol. 2013;25(5):616-22.
148. Brunner HI, Sherrard TM, Klein-Gitelman MS. Cost of treatment of childhood-onset systemic lupus erythematosus. Arthritis Rheum. 2006;55(2):184-8.
149. Mina R, Von Scheven E, Ardoin SP, Eberhard BA, Punaro M, Ilowite N, et al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012;64(3):375-83.
150. Bennett M, Brunner HI. Biomarkers and updates on pediatrics lupus nephritis. Rheum Dis Clin North Am. 2013;39(4):833-53.
151. Sundel R, Solomons N, Lisk L. Aspreva Lupus Management Study (ALMS) Group. Efficacy of mycophenolate mofetil in adolescent patients with lupus nephritis: evidence from a two-phase, prospective randomized trial. Lupus. 2012;21(13):1433-43.
152. Aikawa NE, Sallum AM, Pereira RM, Suzuki L, Viana VS, Bonfa E, Silva CA. Subclinical impairment of ovarian reserve in juvenile systemic lupus erythematosus after cyclophosphamide therapy. Clin Exp Rheumatol. 2012;30(3):445-9.
153. Swan JT, Riche DM, Riche KD, Majithia V. Systematic review and meta-analysis of immunosuppressant therapy clinical trials in membranous lupus nephritis. J Investig Med. 2011;59(2):246-58.
154. Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, et al. Club Rhumatismes et Inflammation. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 2010;62(8):2458-66.
155. Shafi ST, Gupta M. Risk of vascular access thrombosis in patients with systemic lupus erythematosus on hemodialysis. J Vasc Access. 2007;8(2):103-8.
156. Cheigh JS, Stenzel KH. End-stage renal disease in systemic lupus erythematosus. Am J Kid Dis. 1993;21:2-8.
157. Nissenson AR, Port FK. Outcome of end-stage renal disease in patients with rare causes of renal failure. III. Systemic/vascular disorders. Q J Med. 1990;74:63-74.
158. Pollock CA, Ibels LS. Dialysis and transplantation in patients with renal failure due to systemic lupus erythematosus. The Australian and New Zealand experience. Aust N Z J Med. 1987;17:321-5.
159. Szeto CC, Li PKT, Wong TYH, Leung CB, Lui SF. Factors associated with active systemic lupus erythematosus after endstage renal disease. J Rheumatol. 1998;25:1520-5.
160. Bruce IN, Hallett DC, Gladman DD, Urowitz MB. Extrarenal diseas activity in systemic lupus erythematosus is not suppressed by chronic renal insufficiency or renal replacement therapy. J Rheumatol. 1999;26:1490-4.
161. Okano K, Yumura W, Nitta K, Uchida K, Ohnuki T, Kawashima A, Nihei H. Analysis of lupus activity in end-stage renal disease treated by hemodialysis. Intern Med. 2001;40:598-602.
162. Krane NK, Burjak K, Archie M, O'Donovan R. Persistent lupus activity in end-stage renal disease. Am J Kidney Dis. 1999;33:872-9.
163. Ribeiro FM, Leite MAP, Velarde GC, Fabris CL, Santos RC, Lugon JR. Activity of systemic lupus erythematosus in end-stage renal disease patients: study in a Brazilian cohort. Am J Nephrol. 2005;25:596-603.
164. Nossent HC, Swaak TJ, Berden JH. Systemic lupus erythematosus: analysis of disease activity in 55 patients with end-stage renal failure treate with hemodialysis or continous ambulatory peritoneal dialysis. Dutch Working Party on SLE. Am J Med. 1990;89:169-74.
165. Jarrett MP, Santhanam S, Del Greco F. The clinical course of end-stage renal disease in systemic lupus erythematosus. Arch Intern Med. 1983;143:1353-6.
166. Coplon NS, Diskin CJ, Petersen J, Swenson RS. The long-term clinical course of systemic lupus erythematosus in end-stage renal disease. N Engl J Med. 1983;308:186-90.
167. Cheigh JS, Kim H, Stenzel KH, Tapia L, Sullivan JF, Stubenbord W, et al. Systemic lupus erythematosus in patients with end-stage renal disease: long-term follow-up on the prognosis of patients and the evolution of lupus activity. Am J Kidney Dis. 1990;16:189-95.
168. Uramoto KM, Michet CJ, Thumboo J, Sunku J, O'Fallon WM, Gabriel SE. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum. 1999;42:46-50.
169. Ziff M, Helderman JH. Dialysis and transplantation in end-stage lupus nephritis. N Engl J Med. 1983;308:218-9.
170. Rodby RA, Korbet SM, Lewis EJ. Persistence of clinical and serologic activity in patients with systemic lupus erythematosus undergoing peritoneal dialysis. Am J Med. 1987;83:613-8.
171. Lee PT, Fang HC, Chen CL, Chiou YH, Chou KJ, Chung HM. Poor prognosis of end-stage renal disease in systemic lupus erythematosus: a cohort of Chinese patients. Lupus. 2003;12:827-32.
172. Goo YS, Park HC, Choi HY, Kim BS, Park YB, Lee SK, et al. The evolution of lupus activity among patients with end-stage renal disease secondary to lupus nephritis. Yonsei Med J. 2004;45:199-206.
173. Grimbert P, Frappier J, Bedrossian J, Legendre C, Antoine C, Hiesse C, et al. Long-term outcome of kidney transplantation in patients with systemic lupus erythematosus: a multicenter study. Groupe Cooperati de Transplantation d'ile de France Transplantation. 1998;66:1000-3.
174. Ward MM. Outcomes of renal transplantation among patients with end-stage renal disease caused by lupus nephritis. Kidney Int. 2000;57:2136-43.
175. Oliveira CS, D'Oliveira I, Bacchiega AB, Klumb EM, Albuquerque EM, Souza E, et al. Renal transplantation in lupus nephritis: a Brazilian cohort. Lupus. 2012;21(5):570-4, http://dx.doi.org/10.1177/0961203311430220.
176. Moroni G, Tantardini F, Gallelli B, Quaglini S, Banfi G, Poli F, et al. The long-term prognosis of renal transplantation in patients with lupus nephritis. Am J Kidney Dis. 2005;45:903-11.
177. Stone JH, Amend WJ, Criswell LA. Antiphospholipid syndrome in renal transplantation: occurrence of clinical events in 96 consecutive patients with systemic lupus erythematosus. Am J Kidney Dis. 1999;34:1040-7.
178. Bunnapradist S, Chung P, Peng A, Hong A, Chung P, Lee B, et al. Outcomes of renal transplantation for recipients with lupus nephritis: analysis of the Organ Procedure and Transplantation Network database. Transplantation. 2006;82:612-8.
179. Hickman RA, Gordon C. Causes and management of infertility in systemic lupus erythematosus. Rheumatology. 2011;50:1551-8.
180. Huong DLT, Amour Z, Duhuat P, Sbai A, Costedoat N, Wechsler B, Piette JC. Risk of Ovarian Failure and Fertility After Intravenous Cyclophosphamide. A Study in 84 Patients. J Rheumatol. 2002;29(12):2571-6.
181. Carmona F, Font J, Cervera R, Munoz F, Cararach V Balasch J. Obstetrical outcome of pregnancy in patients with systemic Lupus erythematosus. A study of 60 cases. Eur J Obstet Gynecol Reprod Biol. 1999;83(2):137-42. PMID: 10391522.
182. Cortes-Hernandez J, Ordi-Ros J, Paredes F, Casellas M, Castillo F, Vilardell-Tarres M. Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. Rheumatology (Oxford). 2002;41(6):643-50. PMID: 12048290.
183. Lima F, Buchanan NM, Khamashta MA, Kerslake S, Hughes GR. Obstetric outcome in systemic lupus erythematosus. Semin Arthritis Rheum. 1995;25(3):184-92. PMID: 8650588.
184. Witter FR. Management of the high-risk lupus pregnant patient. Rheum Dis Clin North Am. 2007;33(2):253-65, v-vi. Review.PMID: 17499706. www.cdc.gov/vacines/pubs/ ACIP-list.htm [acessado em marco de 2014].
185. Buyon JP. Updates on lupus and pregnancy. Bull NYU Hosp Jt Dis. 2009;67(3):271-5. Review. PMID: 19852749.
186. Clowse ME. Lupus activity in pregnancy. Rheum Dis Clin North Am. 2007;33:237-52. Review. PMID: 17499705.
187. Baer AN, Witter FR, Petri M. Lupus and pregnancy. Obstet Gynecol Suv. 2011;66(10):639-53.
188. Clowse MEB, Jamison M, Myers E, James AH. A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol. 2008;199:127, e1-127.e6.
189. Yuen SY, Krizova A, Ouimet JM, Pope JE. Pregnancy outcome in systemic lupus erythematosus (SLE) is improving: results from a case control study and literature review. Open Rheumatol J. 2008;2:89-98.
190. Clark CA, Spitzer KA, Laskin CA. Decrease in pregnancy loss rates in patients with systemic lupus erythematosus over a 40-year period. J Rheumatol. 2005;32:1709-12.
191. Chakravarty EF, Colon I, Langen ES, Nix DA, El-Sayed YY, Genovese MC, et al. Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. Am J Obstet Gynecol. 2005;192:1897-904.
192. Clowse ME, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006;54:3640-7.
193. Smyth A, Oliveira GHM, Lahr BD, Bailey KR, Norby SM, Garovic VD. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol. 2010;5:2060-8.
194. Moroni G, Ponticelli C. The risk of pregnancy in patients with lupus nephritis. J Nephrol. 2003;16(2):161-7.
195. Qazi UM, Petri M. Autoantibodies, low complement, and obesity predict preeclampsia in SLE: a case-control study. Arthritis Rheum. 2006;54 9 Suppl:S264.
196. Lateef A, Petri M. Management of pregnancy in systemic lupus erythematosus. Nat Rev Rheumatol. 2012;8:710-8.
197. Verghese L, Alam S, Beski S, Thuraisingham R, Barnes I, MacCallum P. Antenatal screening for pre-eclampsia: evaluation of the NICE and pre-eclampsia community guidelines. J Gynecol Obstet. 2012;32(2):128-31.
198. Imbasciati E, Tincani A, Gregorini G, Doria A, Moroni G, Cabiddu G, Marcelli D. Pregnancy in women with pre-existing lupus nephritis: predictors of fetal and maternal outcome. Nephrol Dial Transplant. 2009;24(2):519-25.
199. Klumb EM, Barros LMS, Romeiro L, Jesus NR, Levy RA, Albuquerque EMN. Impacto da nefrite sobre os resultados gestacionais de mulheres com lupus eritematoso sistemico. Rev Bras Reumatol. 2005;45(3):107-13.
200. Ritchie J, Smyth A, Tower C, Helbert M, Venning M, Garovic V. Maternal deaths in women with lupus nephritis: a review of published evidence. Lupus. 2012;21(5):534-41.
201. Stensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther. 2006;8(3):209. PMID: 16712713.
202. Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, et al. Eular recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the Eular Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008;67(2):195-205. PMID: 17504841.
203. Stojan G, Baer AN. Flares of systemic lupus erythematosus during pregnanc and the puerperium: prevention, diagnosis and management. Expert Rev Clin Immunol. 2012;8(5):439-53. PMID: 22882219.
204. Petri M. The Hopkin Lupus Pregnancy Center: ten key issues in management. Rheum Dis Clin North Am. 2007;33:27-35.
205. Diniz-da-Costa T, Centeno M, Pinto L, Marques A, Mendes-Graca L. Systemic lupus erythematosus and pregnancy. Acta Med Port. 2012;25(6):448-53. PMID: 23534598.